Target intelligence / Profile preview

Histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1L)

Target
DOT1L
Molecular classification
Enzyme, Histone methyltransferase, Lysine methyltransferase, Epigenetic regulator, Histone modification
01

Overview

Histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1L) is a highly conserved enzyme that catalyzes mono-, di-, and tri-methylation of lysine 79 on histone H3, a key epigenetic mark regulating chromatin state and gene transcription. Unlike other histone methyltransferases, DOT1L lacks a SET domain and instead utilizes an Adomet-binding motif for transfer of methyl groups from S-adenosyl methionine. DOT1L is critically involved in embryonic development, genomic stability, cell cycle progression, transcriptional regulation, DNA repair, and immune modulation. DOT1L aberrations are implicated in leukemias (especially MLL-rearranged forms) and aggressive solid tumors; it functions both as promoter and suppressor of gene expression according to cellular context. DOT1L represents a novel therapeutic target for epigenetic cancer therapy, with selective inhibitors being clinically investigated, though selectivity and safety remain major challenges[1][2][3][4][5][6][7][8].

Other names
DOT1-like proteinDOT1KMT4KIAA1814Histone H3-K79 methyltransferaseH3-K79-HMTaseLysine N-methyltransferase 4NDNS
02

Mechanism of action

Inhibition of H3K79 methylation Modulation of gene expression via epigenetic blockade Suppression of oncogenic gene transcription, especially *HOXA9* and *HOXA7* in MLLr leukemia[1][4]

03

Biological functions

Epigenetic regulation of gene expressionChromatin remodelingCell cycle regulationCell proliferationDevelopment (embryonic and adult tissues)Transcription elongationDNA repairTelomeric silencingImmune responseHeterochromatin formationMeiotic checkpoint controlStemness and cell plasticity
04

Disease associations

Cancer (notably leukemias, MLL-rearranged leukemia, and various solid tumors: breast, ovarian, prostate, colon)ChemoresistanceDevelopmental disordersPossibly other pathology relating to disrupted epigenetic regulation
05

Safety considerations

Off-target effects due to homology among histone methyltransferases (difficulty in selectivity)Developmental toxicity (essential for embryogenesis)Possible hematopoietic toxicityPotentially global chromatin disruption with inhibition[1][4]
06

Interacting drugs

Pinometostat (EPZ-5676; DOT1L inhibitor)

1 more in the full profile.

07

Biomarkers

H3K79 methylation levelsDOT1L expressionMLL fusion status (for patient selection in leukemia)*HOXA* gene expression profile

Beyond the preview

Go deeper on Histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call